Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/4/2011

al patient data to support the application, and plans to present the new information to the FDA.

Caldolor®

In June 2009, the FDA approved Caldolor, the Company's intravenous formulation of ibuprofen, for marketing in the United States through a priority review. In late 2009, Cumberland launched the product in the U.S. and Caldolor is stocked at wholesalers serving hospitals nationwide.

In 2010, the Company focused its sales and marketing efforts primarily on securing formulary approval nationally for Caldolor. Early in the second quarter of 2011, Cumberland implemented a strategic shift to begin focusing on pull-through activities necessary to build volume of use and bring Caldolor to a larger population of patients in facilities stocking the product.

During the second quarter of 2011, Cumberland also progressed four clinical studies to further evaluate Caldolor in patients.  Two of these trials are designed to support pediatric use, including a pediatric fever study to evaluate safety, efficacy and pharmacokinetics of Caldolor in hospitalized children as well as a pediatric pain study. Two new registry studies will gather additional data in adults, including a study evaluating Caldolor in treating pain and fever in a wide range of hospitalized patients and another evaluating the product for management of pain in surgical patients.  

Hepatoren™

In April 2011, Cumberland entered into an agreement to acquire the rights to ifetroban, a new Phase II product candidate. The Company has initiated clinical development under the brand name Hepatoren™ (ifetroban) Injection and is evaluating the product for treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS), a life-threatening condition involving progressive kidney failure for which there is no U.S. approved pharmaceutical treatment.

Ifetroban was initially developed extensively by a large pharmaceutical
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
5. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
6. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
7. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
8. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
9. Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
10. Cumberland Pharmaceuticals Announces Extension of FDA Review of Acetadote® Supplemental New Drug Application
11. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014   ... today the appointment of J. Patrick Ravenel ... years of enterprise software and systems experience and a ... Fortune 500 companies. "Patrick has been ... class software and systems and is known industry-wide for ...
(Date:10/1/2014)...  SI-BONE, Inc., a medical device company that pioneered the ... invasive surgical (MIS) device indicated for fusion for certain disorders ... its European operations with the formation of a GmbH and ... Manager, Germany.  Mr. Schaber will join former Kyphon colleague ... , Middle East and Asia ...
(Date:10/1/2014)... LAUSANNE , Switzerland , October ... European leader in Clinical Genomics and Next Generation Sequencing ... Solution allowing clinicians to run full cystic fibrosis analysis ... covers the identification and characterisation of all types of ... analytical performance. Until now, it has not ...
Breaking Medicine Technology:Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 2SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 3SI-BONE, Inc. Announces European Expansion with Appointment of Eric Schaber as General Manager, Germany and Formation of GmbH 4Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2
(Date:10/1/2014)... Despite a policy focus on expanding access ... vulnerable population continues to have significant dental disease. ... of the American Dental Association , researchers from ... School of Dental Medicine report on the first ... care provided by caregivers to adults with developmental ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog ... plan for vulnerable family members. , Life insurance plans ... in the family should always carry a life insurance ... the rest of the family. , Clients can ... more from temporary coverage or from a permanent policy. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Phoseon Technology, ... , continues to expand the business worldwide. This rapid ... with additional capacity for manufacturing efforts. The company has ... last five years and expects this growth to continue ... curing technology gains worldwide adoption. , “We are ...
(Date:10/1/2014)... A new genetic finding from Duke Medicine suggests that ... depression might also be hard-wired to gain weight when ... disease. , An estimated 13 percent of people, all ... and knowing this could help them reduce heart disease ... and stress management. , "Genetic susceptibility, psychosocial stress and ...
(Date:10/1/2014)... 2014 Diet Doc understands that many of ... weight and their dieting attempts could be easily sabotaged by ... hormone diet treatments into their programs as a way ... fast and effective weight loss results, it also allows patients ... to maintain their weight for the future. , Earlier versions ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... offers Barry McMillen - Nicotine Cessation Expert and ... ... Using tobacco isn,t just a,habit; it,s an addiction. Hazelden has ... 50 years. The same principles,of the Hazelden treatment experience help tobacco ...
... University Hospitals Case Medical Center finds that Deep ... Tourette Syndrome (TS). This first-of-its-kind study of five ... tic frequency and severity in some people who ... is a neurobehavioral disorder characterized by sudden, repetitive ...
... sent to kill them, study finds , , MONDAY, Nov. ... of molecular weapons that helps make community-associated methicillin-resistant ... work must be done, the study "provides a partial ... causing infection and gives a starting point in the ...
... contribute to high mercury,levels in fish Americans consume, ... dental mercury air,emissions may be more than five times ... The U.S. House,Subcommittee on Domestic Policy of the ... Wednesday, Nov. 14, to discuss FDA,s,responsibility to evaluate the ...
... 12 Indiana Gov. Mitch,Daniels joined executives from ... to announce the company,s plans to build the ... Indiana, filling a growing,nationwide demand for lower-cost medicines. ... 2009, will cover an area equivalent to,six and ...
... AdCare Health,Systems, Inc. (Amex: ADK ) announced ... results on Wednesday, November 14th, 2007. In conjunction,with ... call on November,15th, at 4:15 EST. The telephone ... unable to participate at that time, playback is,available ...
Cached Medicine News:Health News:Quit Smoking Tips For The Great American Smokeout Day - November 15 2Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 2Health News:University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome 3Health News:Key to MRSA Virulence in Community Discovered 2Health News:Key to MRSA Virulence in Community Discovered 3Health News:Environmental Impacts of Dental Mercury Focus of U.S. House Oversight Hearing Wednesday 2Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 2Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 3Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 4Health News:Medco to Build World's Largest, Most Advanced Automated Pharmacy in Central Indiana 5Health News:AdCare Health Systems, Inc. Announces 2007 Third Quarter Earnings Release and Conference Call Schedule 2
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... offer a complete line of ... state-of-the-art monoclonal and monoclonal/polyclonal antibody-based ... of enteric pathogens in fecal ... for Clostridium difficile, Entamoeba histolytica, ...
Medicine Products: